Loading
Nanoparticle-based Drug Delivery / Nanoplatforms for Cancer Theranostics · Journal article
Advanced Functional Materials · August 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a preclinical proof-of-concept study of a chitosan-based implantable platform engineered for localized SN-38 delivery. In vitro release occurred over 90 days with partial biodegradation; in vivo colorectal cancer xenografts showed tumor growth inhibition without apparent systemic toxicity under the tested conditions. The work supports feasibility but provides no comparative efficacy data, quantified tumor response metrics, or safety characterization sufficient to establish clinical potential.
Uncontrolled preclinical in vivo study. HCT116 human colorectal cancer cells implanted as xenografts; specific animal species, age, and cohort details not provided.. Intervention: Implantable bio-inspired biopolymeric platform (crosslinked chitosan, gyroid architecture) loaded with SN-38 (active metabolite of irinotecan)..
Implants provided sustained SN-38 release over 90 days in vitro In vivo HCT116 xenografts demonstrated significant tumor growth inhibition No evidence of systemic toxicity by endpoint measures tested
Systemic toxicity assessment limited to unspecified endpoint measures; pharmacokinetics and biodistribution not characterized. No evidence of systemic toxicity by endpoint measures tested
This is early-stage preclinical work demonstrating platform feasibility for localized drug delivery; does not yet inform clinical decision-making. Progression would require comparative efficacy studies, quantified biodistribution, comprehensive toxicology, and translation to relevant solid tumor models.
First-in-vivo proof-of-concept of a novel implantable drug delivery platform in xenograft model; demonstrates feasibility but lacks comparative control arm, detailed efficacy metrics, and systemic biodistribution data needed for clinical translation.
As stated by the source record.
Quoted from the source exactly as published.
This is early-stage preclinical work demonstrating platform feasibility for localized drug delivery; does not yet inform clinical decision-making. Progression would require comparative efficacy studies, quantified biodistribution, comprehensive toxicology, and translation to relevant solid tumor models.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
ABSTRACT The development of biocompatible and biodegradable drug delivery systems remains a major challenge in cancer therapy, particularly for the localized and sustained release of poorly soluble, unstable, and highly toxic compounds. 7‐Ethyl‐10‐hydroxycamptothecin (SN‐38), the active metabolite of irinotecan, offers superior anticancer efficacy but suffers from the aforementioned drawbacks, limiting its clinical use. The use of its prodrug, irinotecan, improves its solubility and stability and is the treatment of choice for many types of malignancies, though its systemic administration in cancer patients leads to significant side effects due to off‐target exposure. Here, a bio‐inspired, implantable biopolymeric platform based on crosslinked chitosan for localized and sustained SN‐38 delivery is presented. Engineered using 3D printed molds into a gyroid architecture, the implants provide sustained SN‐38 release over 90 days in vitro with partial biodegradation in vitro. In vivo studies using HCT116 human colorectal cancer xenografts demonstrate significant tumor growth inhibition without evidence of systemic toxicity by under the conditions tested. This platform showcases a functional materials approach to overcome key limitations in conventional drug delivery technologies and supports the feasibility of localized chemotherapy delivery to solid tumors.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.